Drug Royalty 3

Drug Royalty III is a $1.45 billion healthcare royalty fund managed by DRI Capital, a leading pioneer in the pharmaceutical royalty investment space. Launched in 2013, the fund specializes in acquiring royalty interests in high-quality, approved, or late-stage life sciences products from global pharmaceutical companies, academic institutions, and research organizations. Its portfolio has included significant royalty streams from blockbuster therapies such as Keytruda (pembrolizumab) for oncology and Zytiga (abiraterone acetate) for prostate cancer. By providing non-dilutive capital to innovators, the fund enables the further development of medical technologies while securing long-term cash flows for its institutional investors. The fund reached its investment capacity and was eventually liquidated following the successful harvest of its royalty assets.